



SPANISH SECURITIES MARKET COMMISSION (CNMV)

CLÍNICA BAVIERA, S.A., on behalf of Aier Eye International (Europe), S.L.U. (the “**Selling Shareholder**”) in compliance with the requirements set forth in article 17 of Regulation (EU) 596/2014 and article 228 of the restated text of the Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, notifies the following,

SIGNIFICANT INFORMATION ANNOUNCEMENT

Further to the significant information announcement released yesterday (register number 267536), in connection with the private placement of a block of ordinary shares of Clínica Baviera, S.A. (the “**Issuer**”), by Ahorro Corporación Financiera, S.V., S.A.U., acting as sole bookrunner, on behalf of the Selling Shareholder, a company controlled by Aier Eye International (Hong Kong) Limited, which is in turn controlled by Aier Eye Hospital Group Co. LTD, the Selling Shareholder hereby announces the completion of the accelerated bookbuilding (“**ABB**”) among qualified investors.

The Selling Shareholder announces that the definitive number of placed shares has been 1,141,531 shares, representing approximately 7% of the share capital of the Issuer. The definitive price at which the Selling Shareholder will sell the shares in the ABB is of €11.50 per share, representing gross proceeds of €13,127,606.50 for the Selling Shareholder.

Following the ABB, the Selling Shareholder or affiliates thereof will continue to hold 13,017,979 ordinary shares of the Issuer, representing approximately 79.83% of its issued share capital.

Subject to certain customary exceptions, the Selling Shareholder has undertaken not to dispose of its ordinary shares except with the prior consent of the sole bookrunners for a period of 90 days from the date hereof.

Madrid, 4 July 2018.

Antonio Peral Ortiz de la Torre

Deputy Secretary of the Board of Directors

IMPORTANT INFORMATION

This document is not for publication or distribution, directly or indirectly, in or into the United States of America, Canada, Australia or Japan or any country or jurisdiction where the distribution of such document is restricted by law.

The securities herein referred to have not been and will not be registered under the U.S. Securities act of 1933 or under other supervisory authority of any State or jurisdiction of the United States of America, or the applicable securities laws of Canada, Australia or Japan. Accordingly, the securities may not be offered, exercised or sold in the United States, Canada, Australia or Japan, or in any other country or jurisdiction other than in compliance with the applicable laws of that country or jurisdiction, or on behalf or for the benefit of any person in the United States, Canada, Australia or Japan.